Scolaris Content Display Scolaris Content Display

Cromoscopia versus endoscopia convencional para la detección de pólipos en el colon y el recto

Appendices

Appendix 1. Cochrane Central Register of Controlled Trials search strategy

Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library), issue 10 2015.

#1 MeSH descriptor: [Colon] explode all trees
#2 MeSH descriptor: [Rectum] explode all trees
#3 MeSH descriptor: [Anal Canal] explode all trees
#4 MeSH descriptor: [Colorectal Neoplasms] explode all trees
#5 MeSH descriptor: [Colonic Polyps] explode all trees
#6 ((colorect* or colon* or large bowel or rect* or anal or anus or gastric*) and (polyp* or neoplas* or tumour* or tumor or adenom* or lesion* or carcinom* adenocarcinom* or cancer*)):ti,ab,kw
#7 (#1 or #2 or #3 or #4 or #5 or #6)
#8 MeSH descriptor: [Endoscopy, Gastrointestinal] explode all trees
#9 (endoscop* or colonoscop* or proctoscop* or gastroscop*):ti,ab,kw
#10 (#8 or #9)
#11 MeSH descriptor: [Indigo Carmine] explode all trees
#12 MeSH descriptor: [Coloring Agents] explode all trees
#13 (chromoscop* or chromo‐endoscop* or chromoendoscop* or magnifying endoscop* or high resolution endoscop* or high resolution colonoscop* or dye spray* or dye‐spray* or indigo* or indigo‐carmine or acetic acid):ti,ab,kw
#14 #11 or #12 or #13)
#15 (#7 and #10 and #14) 

Appendix 2. MEDLINE search strategy

MEDLINE (Ovid) 1950 to 26.10.2015
1. exp Colon/
2. exp Rectum/
3. exp Anal Canal/
4. exp Colorectal Neoplasms/
5. exp Colonic Polyps/
6. ((colorect* or colon* or large bowel or rect* or anal or anus or gastric*) and (polyp* or neoplas* or tumour* or tumor or adenom* or lesion* or carcinom* adenocarcinom* or cancer*)).mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Endoscopy, Gastrointestinal/
9. (endoscop* or colonoscop* or proctoscop* or gastroscop*).mp.
10. 8 or 9
11. exp Indigo Carmine/
12. exp Coloring Agents/
13. (chromoscop* or chromo‐endoscop* or chromoendoscop* or magnifying endoscop* or high resolution endoscop* or high resolution colonoscop* or dye spray* or dye‐spray* or indigo* or indigo‐carmine or acetic acid).mp.
14. 11 or 12 or 13
15. 7 and 10 and 14
16. randomized controlled trial.pt.
17. controlled clinical trial.pt.
18. randomized.ab.
19. placebo.ab.
20. clinical trial.sh.
21. randomly.ab.
22. trial.ti.
23. 16 or 17 or 18 or 19 or 20 or 21 or 22
24. humans.sh.
25. 23 and 24
26. 15 and 25

Appendix 3. EMBASE search strategy

EMBASE (Ovid) 1974 to 26.10.2015
1. exp colon/
2. exp rectum/
3. exp colon tumor/
4. exp rectum tumor/
5. exp intestine polyp/
6. ((colorect* or colon* or large bowel or rect* or anal or anus) and (polyp* or neoplas* or tumour* or tumor or adenom* or lesion* or carcinom* adenocarcinom* or cancer*)).m_titl.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp gastrointestinal endoscopy/
9. exp gastroscope/
10. exp proctoscope/
11. exp colonoscope/
12. (endoscop* or colonoscop* or proctoscop* or gastroscop*).mp.
13. 8 or 9 or 10 or 11 or 12
14. exp coloring agent/
15. exp chromo‐endoscopy/
16. exp dye/
17. exp high resolution endoscopy/
18. exp magnifying endoscopy/
19. (chromoscop* or chromo‐endoscop* or chromoendoscop* or magnifying endoscop* or high resolution endoscop* or high resolution colonoscop* or dye spray* or dye‐spray* or indigo* or indigo‐carmine or acetic acid).mp.
20. 14 or 15 or 16 or 17 or 18 or 19
21. 7 and 13 and 20
22. CROSSOVER PROCEDURE.sh.
23. DOUBLE‐BLIND PROCEDURE.sh.
24. SINGLE‐BLIND PROCEDURE.sh.
25. (crossover* or cross over*).ti,ab.
26. placebo*.ti,ab.
27. (doubl* adj blind*).ti,ab.
28. allocat*.ti,ab.
29. trial.ti.
30. RANDOMIZED CONTROLLED TRIAL.sh.
31. random*.ti,ab.
32. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
33. (exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans or man or men or woman).ti.)
34. 32 not 33
35. 21 and 34

Appendix 4. Criteria for judging risk of bias in the 'Risk of bias' assessment tool

RANDOM SEQUENCE GENERATION

Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence

Criteria for a judgement of ‘Low risk’ of bias

The investigators describe a random component in the sequence generation process such as:

  • Referring to a random number table;

  • Using a computer random number generator;

  • Coin tossing;

  • Shuffling cards or envelopes;

  • Throwing dice;

  • Drawing of lots;

  • Minimisation*.

*Minimisation may be implemented without a random element, and this is considered to be equivalent to being random

Criteria for a judgement of ‘High risk’ of bias

The investigators describe a non‐random component in the sequence generation process. Usually, the description would involve some systematic, non‐random approach, for example:

  • Sequence generated by odd or even date of birth;

  • Sequence generated by some rule based on date (or day) of admission;

  • Sequence generated by some rule based on hospital or clinic record number.

  • Other non‐random approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious. They usually involve judgement or some method of non‐random categorisation of participants, for example:

    • Allocation by judgement of the clinician;

    • Allocation by preference of the participant;

    • Allocation based on the results of a laboratory test or a series of tests;

    • Allocation by availability of the intervention.

Criteria for a judgement of ‘Unclear risk’ of bias

Insufficient information about the sequence generation process to permit judgement of ‘Low risk’ or ‘High risk’

ALLOCATION CONCEALMENT

Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment

Criteria for a judgement of ‘Low risk’ of bias

Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation:

  • Central allocation (including telephone, web‐based, and pharmacy‐controlled randomisation);

  • Sequentially numbered drug containers of identical appearance;

  • Sequentially numbered, opaque, sealed envelopes.

Criteria for a judgement of ‘High risk’ of bias

Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on:

  • Using an open random allocation schedule (e.g. a list of random numbers);

  • Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or not sequentially numbered);

  • Alternation or rotation;

  • Date of birth;

  • Case record number;

  • Any other explicitly unconcealed procedure.

Criteria for a judgement of ‘Unclear risk’ of bias

Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement – for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque, and sealed

BLINDING OF PARTICIPANTS AND PERSONNEL

Performance bias due to knowledge of the allocated interventions by participants and personnel during the study

Criteria for a judgement of ‘Low risk’ of bias

Any one of the following:

  • No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding;

  • Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

Criteria for a judgement of ‘High risk’ of bias

Any one of the following:

  • No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding;

  • Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.

Criteria for a judgement of ‘Unclear risk’ of bias

Any one of the following:

  • Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’;

  • The study did not address this outcome.

BLINDING OF OUTCOME ASSESSMENT

Detection bias due to knowledge of the allocated interventions by outcome assessors

Criteria for a judgement of ‘Low risk’ of bias

Any one of the following:

  • No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;

  • Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

Criteria for a judgement of ‘High risk’ of bias

Any one of the following:

  • No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding;

  • Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Criteria for a judgement of ‘Unclear risk’ of bias

Any one of the following:

  • Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’;

  • The study did not address this outcome.

INCOMPLETE OUTCOME DATA

Attrition bias due to amount, nature, or handling of incomplete outcome data

Criteria for a judgement of ‘Low risk’ of bias

Any one of the following:

  • No missing outcome data;

  • Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);

  • Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;

  • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;

  • For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;

  • Missing data have been imputed using appropriate methods.

Criteria for a judgement of ‘High risk’ of bias

Any one of the following:

  • Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;

  • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;

  • For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;

  • ‘As‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation;

  • Potentially inappropriate application of simple imputation.

Criteria for a judgement of ‘Unclear risk’ of bias

Any one of the following:

  • Insufficient reporting of attrition/exclusions to permit judgement of ‘Low risk’ or ‘High risk’ (e.g. number randomised not stated, no reasons for missing data provided);

  • The study did not address this outcome.

SELECTIVE REPORTING

Reporting bias due to selective outcome reporting

Criteria for a judgement of ‘Low risk’ of bias

Any of the following:

  • The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way;

  • The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon).

Criteria for a judgement of ‘High risk’ of bias

Any one of the following:

  • Not all of the study’s prespecified primary outcomes have been reported;

  • One or more primary outcomes are reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that were not prespecified;

  • One or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);

  • One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis;

  • The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Criteria for a judgement of ‘Unclear risk’ of bias

Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’. It is likely that the majority of studies will fall into this category.

OTHER BIAS

Bias due to problems not covered elsewhere in the table

Criteria for a judgement of ‘Low risk’ of bias

The study appears to be free of other sources of bias.

Criteria for a judgement of ‘High risk’ of bias

There is at least one important risk of bias. For example, the study:

  • Had a potential source of bias related to the specific study design used; or

  • Has been claimed to have been fraudulent; or

  • Had some other problem.

Criteria for a judgement of ‘Unclear risk’ of bias

There may be a risk of bias, but there is either:

  • Insufficient information to assess whether an important risk of bias exists; or

  • Insufficient rationale or evidence that an identified problem will introduce bias.

Appendix 5. Overall risk of bias

The design of chromoscopy studies has one inherent and unavoidable risk of bias, which is that the participant and investigator cannot be blinded because it is not possible to be unaware that you are using chromoscopy. In some trials one aspect of blinding, that of an increased time taken to carry out the procedure, is controlled for, so that although the risk of bias due to blinding is universal, it has been reduced. Blinding aside, three generic markers of internal validity (random sequence generation, allocation concealment, and selective reporting) are generally good in almost all trials. One generic marker essentially related to intention to treat is unclear from the trial reports of six studies and remains unclear after attempts to contact the authors. Although the lack of blinding is known to influence the overall results, we would suggest that given the general low risk or unclear risk of bias in the other domains, the overall risk of bias is neither high nor low, which justifies our overall grading as unclear.

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Figuras y tablas -
Figure 1

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figuras y tablas -
Figure 2

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Study flow diagram.
Figuras y tablas -
Figure 3

Study flow diagram.

Forest plot of comparison: 1 Total number polyps (neoplastic and non‐neoplastic) detected, outcome: 1.1 Total polyps (neoplastic and non‐neoplastic) detected.
Figuras y tablas -
Figure 4

Forest plot of comparison: 1 Total number polyps (neoplastic and non‐neoplastic) detected, outcome: 1.1 Total polyps (neoplastic and non‐neoplastic) detected.

Forest plot of comparison: 2 Total number of neoplastic lesions detected, outcome: 2.1 Total neoplastic lesions.
Figuras y tablas -
Figure 5

Forest plot of comparison: 2 Total number of neoplastic lesions detected, outcome: 2.1 Total neoplastic lesions.

Forest plot of comparison: 3 Total number of participants with at least one polyp (neoplastic or non‐neoplastic) detected, outcome: 3.1 Number of participants with at least one polyp (neoplastic or non‐neoplastic) detected.
Figuras y tablas -
Figure 6

Forest plot of comparison: 3 Total number of participants with at least one polyp (neoplastic or non‐neoplastic) detected, outcome: 3.1 Number of participants with at least one polyp (neoplastic or non‐neoplastic) detected.

Forest plot of comparison: 4 Total number of participants with at least one neoplastic lesion detected, outcome: 4.1 Total participants with at least one neoplastic lesion.
Figuras y tablas -
Figure 7

Forest plot of comparison: 4 Total number of participants with at least one neoplastic lesion detected, outcome: 4.1 Total participants with at least one neoplastic lesion.

Comparison 1 Total number polyps (neoplastic and non‐neoplastic) detected, Outcome 1 Total polyps (neoplastic and non‐neoplastic) detected.
Figuras y tablas -
Analysis 1.1

Comparison 1 Total number polyps (neoplastic and non‐neoplastic) detected, Outcome 1 Total polyps (neoplastic and non‐neoplastic) detected.

Comparison 1 Total number polyps (neoplastic and non‐neoplastic) detected, Outcome 2 Total polyps (neoplastic and non‐neoplastic) in proximal colon.
Figuras y tablas -
Analysis 1.2

Comparison 1 Total number polyps (neoplastic and non‐neoplastic) detected, Outcome 2 Total polyps (neoplastic and non‐neoplastic) in proximal colon.

Comparison 1 Total number polyps (neoplastic and non‐neoplastic) detected, Outcome 3 Total polyps (neoplastic and non‐neoplastic) in distal colon.
Figuras y tablas -
Analysis 1.3

Comparison 1 Total number polyps (neoplastic and non‐neoplastic) detected, Outcome 3 Total polyps (neoplastic and non‐neoplastic) in distal colon.

Comparison 2 Total number of neoplastic lesions detected, Outcome 1 Total neoplastic lesions.
Figuras y tablas -
Analysis 2.1

Comparison 2 Total number of neoplastic lesions detected, Outcome 1 Total neoplastic lesions.

Comparison 2 Total number of neoplastic lesions detected, Outcome 2 Total neoplastic lesions in proximal colon.
Figuras y tablas -
Analysis 2.2

Comparison 2 Total number of neoplastic lesions detected, Outcome 2 Total neoplastic lesions in proximal colon.

Comparison 2 Total number of neoplastic lesions detected, Outcome 3 Total neoplastic lesions in distal colon.
Figuras y tablas -
Analysis 2.3

Comparison 2 Total number of neoplastic lesions detected, Outcome 3 Total neoplastic lesions in distal colon.

Comparison 2 Total number of neoplastic lesions detected, Outcome 4 Total neoplastic lesions in studies with single intubation and controlled extubation.
Figuras y tablas -
Analysis 2.4

Comparison 2 Total number of neoplastic lesions detected, Outcome 4 Total neoplastic lesions in studies with single intubation and controlled extubation.

Comparison 3 Total number of participants with at least one polyp (neoplastic or non‐neoplastic) detected, Outcome 1 Number of participants with at least one polyp (neoplastic or non‐neoplastic) detected.
Figuras y tablas -
Analysis 3.1

Comparison 3 Total number of participants with at least one polyp (neoplastic or non‐neoplastic) detected, Outcome 1 Number of participants with at least one polyp (neoplastic or non‐neoplastic) detected.

Comparison 3 Total number of participants with at least one polyp (neoplastic or non‐neoplastic) detected, Outcome 2 Participants with at least one polyp (neoplastic or non‐neoplastic) in the proximal colon in single intubation trials.
Figuras y tablas -
Analysis 3.2

Comparison 3 Total number of participants with at least one polyp (neoplastic or non‐neoplastic) detected, Outcome 2 Participants with at least one polyp (neoplastic or non‐neoplastic) in the proximal colon in single intubation trials.

Comparison 3 Total number of participants with at least one polyp (neoplastic or non‐neoplastic) detected, Outcome 3 Participants with at least one polyp (neoplastic or non‐neoplastic) in the distal colon in single intubation trials.
Figuras y tablas -
Analysis 3.3

Comparison 3 Total number of participants with at least one polyp (neoplastic or non‐neoplastic) detected, Outcome 3 Participants with at least one polyp (neoplastic or non‐neoplastic) in the distal colon in single intubation trials.

Comparison 4 Total number of participants with at least one neoplastic lesion detected, Outcome 1 Total participants with at least one neoplastic lesion.
Figuras y tablas -
Analysis 4.1

Comparison 4 Total number of participants with at least one neoplastic lesion detected, Outcome 1 Total participants with at least one neoplastic lesion.

Comparison 4 Total number of participants with at least one neoplastic lesion detected, Outcome 2 Participants with at least one neoplastic lesion in proximal colon.
Figuras y tablas -
Analysis 4.2

Comparison 4 Total number of participants with at least one neoplastic lesion detected, Outcome 2 Participants with at least one neoplastic lesion in proximal colon.

Comparison 4 Total number of participants with at least one neoplastic lesion detected, Outcome 3 Participants with at least one neoplastic lesion in the distal colon.
Figuras y tablas -
Analysis 4.3

Comparison 4 Total number of participants with at least one neoplastic lesion detected, Outcome 3 Participants with at least one neoplastic lesion in the distal colon.

Comparison 5 Number of diminutive neoplastic lesions detected with each intervention, Outcome 1 Number of diminutive neoplastic lesions.
Figuras y tablas -
Analysis 5.1

Comparison 5 Number of diminutive neoplastic lesions detected with each intervention, Outcome 1 Number of diminutive neoplastic lesions.

Comparison 5 Number of diminutive neoplastic lesions detected with each intervention, Outcome 2 Number of diminutive neoplastic lesions in the proximal colon.
Figuras y tablas -
Analysis 5.2

Comparison 5 Number of diminutive neoplastic lesions detected with each intervention, Outcome 2 Number of diminutive neoplastic lesions in the proximal colon.

Comparison 5 Number of diminutive neoplastic lesions detected with each intervention, Outcome 3 Number of diminutive neoplastic lesions in the distal colon.
Figuras y tablas -
Analysis 5.3

Comparison 5 Number of diminutive neoplastic lesions detected with each intervention, Outcome 3 Number of diminutive neoplastic lesions in the distal colon.

Comparison 6 Number of participants with at least one diminutive neoplastic lesion detected with each intervention, Outcome 1 Participants with diminutive neoplastic lesions.
Figuras y tablas -
Analysis 6.1

Comparison 6 Number of participants with at least one diminutive neoplastic lesion detected with each intervention, Outcome 1 Participants with diminutive neoplastic lesions.

Comparison 6 Number of participants with at least one diminutive neoplastic lesion detected with each intervention, Outcome 2 Participants with diminutive neoplastic lesions in the proximal colon.
Figuras y tablas -
Analysis 6.2

Comparison 6 Number of participants with at least one diminutive neoplastic lesion detected with each intervention, Outcome 2 Participants with diminutive neoplastic lesions in the proximal colon.

Comparison 6 Number of participants with at least one diminutive neoplastic lesion detected with each intervention, Outcome 3 Participants with diminutive neoplastic lesions in the distal colon.
Figuras y tablas -
Analysis 6.3

Comparison 6 Number of participants with at least one diminutive neoplastic lesion detected with each intervention, Outcome 3 Participants with diminutive neoplastic lesions in the distal colon.

Comparison 7 Number of participants with three or more neoplastic lesions detected with each intervention, Outcome 1 Number of participants with 3 or more adenomas.
Figuras y tablas -
Analysis 7.1

Comparison 7 Number of participants with three or more neoplastic lesions detected with each intervention, Outcome 1 Number of participants with 3 or more adenomas.

Summary of findings for the main comparison. Chromoscopy compared to conventional colonoscopy for the detection of polyps

Chromoscopy compared to conventional colonoscopy for the detection of polyps

Patient or population: people undergoing colonoscopy for the detection of polyps

Settings: those patients undergoing endoscopy for investigation of gastrointestinal symptoms, as part of a screening programme or surveillance for colorectal neoplasia due to a family history of colorectal cancer, previous polyp detection, or a previous colorectal cancer resection

Intervention: pan‐chromoscopy

Comparison: conventional colonoscopy

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Assumed risk

Corresponding risk

Conventional colonoscopy

Pan‐chromoscopy

Total polyps (neoplastic and non‐neoplastic) detected

The mean total polyps ranged across control groups from
0.4 to 2.1

The mean total polyps in the intervention group was
1.91 (1.3 to 3.1)

MD 0.89 (0.74 to 1.04)

2727 (7)

⊕⊕⊝⊝
low

Total neoplastic lesions

The mean total neoplastic lesions ranged across control groups from
0.2 to 1.1

The mean total neoplastic lesions in the intervention groups was
0.89 (0.6 to 1.3)

MD 0.33 (0.25 to 0.41)

2727 (7)

⊕⊕⊝⊝
low

Number of participants with at least 1 polyp (neoplastic or non‐neoplastic)

529 per 1000

676 per 1000
(589 to 704)

OR 1.87 (1.51 to 2.30)

1515 (4)

⊕⊕⊝⊝
low

Total participants with at least 1 neoplastic lesion

380 per 1000

481 per 1000
(331 to 648)

OR 1.53 (1.31 to 1.79)

2727 (7)

⊕⊕⊝⊝
low

Number of diminutive neoplastic lesions

The mean number of diminutive polyps ranged across control groups from
0.27 to 0.7

The mean number of diminutive polyps in the intervention groups was
0.63 (0.4 to 0.8)

MD 0.21 (0.10 to 0.32)

1409 (4)

⊕⊕⊝⊝
low

Participants with diminutive neoplastic lesions

170 per 1000

236 per 1000
(165 to 373)

OR 1.51 (1.19 to 1.92)

1757 (4)

⊕⊕⊝⊝
low

Number of participants with 3 or more adenomas (in studies with single intubation)

26 per 1000

111 per 1000
(101 to 121)

OR 4.63 (1.99 to 10.80)

519 (2)

⊕⊕⊝⊝
low

Adverse events

Unestimable as no data supplied

Unestimable as no data supplied

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MD: mean difference; OR: odds ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

The nature of diminutive polyp detection means that it is likely that some of the included studies are underpowered. Furthermore, significant heterogeneity is introduced by the variability of the colonoscopes used in the studies as well as the differences in dye‐spraying technique. There are also subtle but clear differences in the study inclusion criteria that affect the quality of the pooled evidence.

Figuras y tablas -
Summary of findings for the main comparison. Chromoscopy compared to conventional colonoscopy for the detection of polyps
Comparison 1. Total number polyps (neoplastic and non‐neoplastic) detected

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total polyps (neoplastic and non‐neoplastic) detected Show forest plot

7

2727

Mean Difference (IV, Fixed, 95% CI)

0.89 [0.74, 1.04]

1.1 Total polyps in studies with single intubation

5

2385

Mean Difference (IV, Fixed, 95% CI)

0.95 [0.77, 1.12]

1.2 Total polyps in studies with double intubation

2

342

Mean Difference (IV, Fixed, 95% CI)

0.73 [0.43, 1.03]

2 Total polyps (neoplastic and non‐neoplastic) in proximal colon Show forest plot

5

1521

Mean Difference (IV, Fixed, 95% CI)

0.34 [0.24, 0.44]

2.1 Total polyps in proximal colon in studies with single intubation

3

1179

Mean Difference (IV, Fixed, 95% CI)

0.31 [0.20, 0.43]

2.2 Total polyps in proximal colon in studies with double intubation

2

342

Mean Difference (IV, Fixed, 95% CI)

0.40 [0.22, 0.59]

3 Total polyps (neoplastic and non‐neoplastic) in distal colon Show forest plot

5

1521

Mean Difference (IV, Fixed, 95% CI)

0.51 [0.41, 0.60]

3.1 Total polyps in distal colon in studies with single intubation

3

1179

Mean Difference (IV, Fixed, 95% CI)

0.62 [0.50, 0.73]

3.2 Total polyps in distal colon in studies with double intubation

2

342

Mean Difference (IV, Fixed, 95% CI)

0.29 [0.13, 0.45]

Figuras y tablas -
Comparison 1. Total number polyps (neoplastic and non‐neoplastic) detected
Comparison 2. Total number of neoplastic lesions detected

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total neoplastic lesions Show forest plot

7

2727

Mean Difference (IV, Fixed, 95% CI)

0.33 [0.25, 0.41]

1.1 Total neoplastic lesions in studies with single intubation

5

2385

Mean Difference (IV, Fixed, 95% CI)

0.34 [0.25, 0.43]

1.2 Total neoplastic lesions in studies with double intubation

2

342

Mean Difference (IV, Fixed, 95% CI)

0.30 [0.12, 0.49]

2 Total neoplastic lesions in proximal colon Show forest plot

6

2529

Mean Difference (IV, Fixed, 95% CI)

0.27 [0.19, 0.35]

2.1 Total neoplastic lesions in proximal colon in studies with single intubation

4

2187

Mean Difference (IV, Fixed, 95% CI)

0.24 [0.15, 0.33]

2.2 Total neoplastic lesions in proximal colon in studies with double intubation

2

342

Mean Difference (IV, Fixed, 95% CI)

0.35 [0.20, 0.50]

3 Total neoplastic lesions in distal colon Show forest plot

5

1869

Mean Difference (IV, Fixed, 95% CI)

0.08 [‐0.00, 0.17]

3.1 Total neoplastic lesions in distal colon in studies with single intubation

3

1527

Mean Difference (IV, Fixed, 95% CI)

0.11 [0.01, 0.21]

3.2 Total neoplastic lesions in distal colon in studies with single intubation

2

342

Mean Difference (IV, Fixed, 95% CI)

0.02 [‐0.14, 0.18]

4 Total neoplastic lesions in studies with single intubation and controlled extubation Show forest plot

4

2126

Mean Difference (IV, Fixed, 95% CI)

0.28 [0.18, 0.38]

Figuras y tablas -
Comparison 2. Total number of neoplastic lesions detected
Comparison 3. Total number of participants with at least one polyp (neoplastic or non‐neoplastic) detected

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of participants with at least one polyp (neoplastic or non‐neoplastic) detected Show forest plot

4

1515

Odds Ratio (M‐H, Fixed, 95% CI)

1.87 [1.51, 2.30]

1.1 Number of participants with at least one polyp (neoplastic and non‐neoplastic detected in studies with single intubation

3

1465

Odds Ratio (M‐H, Fixed, 95% CI)

1.83 [1.48, 2.27]

1.2 Number of participants with at least one polyp (neoplastic and non‐neoplastic) detected in studies with double intubation

1

50

Odds Ratio (M‐H, Fixed, 95% CI)

3.19 [1.00, 10.17]

2 Participants with at least one polyp (neoplastic or non‐neoplastic) in the proximal colon in single intubation trials Show forest plot

1

259

Odds Ratio (M‐H, Fixed, 95% CI)

1.87 [1.10, 3.16]

3 Participants with at least one polyp (neoplastic or non‐neoplastic) in the distal colon in single intubation trials Show forest plot

1

259

Odds Ratio (M‐H, Fixed, 95% CI)

1.92 [1.14, 3.24]

Figuras y tablas -
Comparison 3. Total number of participants with at least one polyp (neoplastic or non‐neoplastic) detected
Comparison 4. Total number of participants with at least one neoplastic lesion detected

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total participants with at least one neoplastic lesion Show forest plot

7

2727

Odds Ratio (M‐H, Fixed, 95% CI)

1.53 [1.31, 1.79]

1.1 Total participants with at least one neoplastic lesion in studies with single intubation

5

2385

Odds Ratio (M‐H, Fixed, 95% CI)

1.56 [1.32, 1.83]

1.2 Total participants with at least one neoplastic lesion in studies with double intubation

2

342

Odds Ratio (M‐H, Fixed, 95% CI)

1.38 [0.89, 2.14]

2 Participants with at least one neoplastic lesion in proximal colon Show forest plot

2

551

Odds Ratio (M‐H, Fixed, 95% CI)

1.55 [1.04, 2.30]

2.1 Participants with at least one neoplastic lesion in the proximal colon in studies with single intubation

1

259

Odds Ratio (M‐H, Fixed, 95% CI)

1.53 [0.85, 2.77]

2.2 Participants with at least one neoplastic lesion in the proximal colon in studies with double intubation

1

292

Odds Ratio (M‐H, Fixed, 95% CI)

1.56 [0.91, 2.67]

3 Participants with at least one neoplastic lesion in the distal colon Show forest plot

2

551

Odds Ratio (M‐H, Fixed, 95% CI)

1.24 [0.79, 1.94]

3.1 Participants with at least one neoplastic lesion in the distal colon in studies with single intubation

1

259

Odds Ratio (M‐H, Fixed, 95% CI)

1.37 [0.65, 2.92]

3.2 Participants with at least one neoplastic lesion in the distal colon in studies with double intubation

1

292

Odds Ratio (M‐H, Fixed, 95% CI)

1.17 [0.67, 2.05]

Figuras y tablas -
Comparison 4. Total number of participants with at least one neoplastic lesion detected
Comparison 5. Number of diminutive neoplastic lesions detected with each intervention

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of diminutive neoplastic lesions Show forest plot

4

1409

Mean Difference (IV, Fixed, 95% CI)

0.21 [0.10, 0.32]

1.1 Number of diminutive neoplastic lesions in studies with single intubation

3

1117

Mean Difference (IV, Fixed, 95% CI)

0.19 [0.07, 0.31]

1.2 Number of diminutive neoplastic lesions in studies with double intubation

1

292

Mean Difference (IV, Fixed, 95% CI)

0.29 [0.06, 0.52]

2 Number of diminutive neoplastic lesions in the proximal colon Show forest plot

2

551

Mean Difference (IV, Fixed, 95% CI)

0.27 [0.10, 0.44]

2.1 Number of diminutive neoplastic lesions in the proximal colon in studies with single intubation

1

259

Mean Difference (IV, Fixed, 95% CI)

0.37 [0.13, 0.61]

2.2 Number of diminutive neoplastic lesions in the proximal colon in studies with double intubation

1

292

Mean Difference (IV, Fixed, 95% CI)

0.18 [‐0.05, 0.41]

3 Number of diminutive neoplastic lesions in the distal colon Show forest plot

2

551

Mean Difference (IV, Fixed, 95% CI)

0.10 [‐0.07, 0.26]

3.1 Number of diminutive neoplastic lesions in the proximal colon in studies with single intubation

1

259

Mean Difference (IV, Fixed, 95% CI)

0.08 [‐0.16, 0.32]

3.2 Number of diminutive neoplastic lesions in the proximal colon in studies with double intubation

1

292

Mean Difference (IV, Fixed, 95% CI)

0.11 [‐0.12, 0.34]

Figuras y tablas -
Comparison 5. Number of diminutive neoplastic lesions detected with each intervention
Comparison 6. Number of participants with at least one diminutive neoplastic lesion detected with each intervention

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Participants with diminutive neoplastic lesions Show forest plot

4

1757

Odds Ratio (M‐H, Fixed, 95% CI)

1.51 [1.19, 1.92]

1.1 Participants with diminutive neoplastic lesions in studies with single intubation

3

1465

Odds Ratio (M‐H, Fixed, 95% CI)

1.46 [1.12, 1.91]

1.2 Participants with diminutive neoplastic lesions in studies with double intubation

1

292

Odds Ratio (M‐H, Fixed, 95% CI)

1.73 [1.03, 2.90]

2 Participants with diminutive neoplastic lesions in the proximal colon Show forest plot

2

551

Odds Ratio (M‐H, Fixed, 95% CI)

2.01 [1.29, 3.15]

2.1 Participants with diminutive neoplastic lesions in the proximal colon in studies with single intubation

1

259

Odds Ratio (M‐H, Fixed, 95% CI)

1.95 [1.03, 3.68]

2.2 Participants with diminutive neoplastic lesions in the proximal colon in studies with double intubation

1

292

Odds Ratio (M‐H, Fixed, 95% CI)

2.08 [1.11, 3.89]

3 Participants with diminutive neoplastic lesions in the distal colon Show forest plot

2

551

Odds Ratio (M‐H, Fixed, 95% CI)

1.37 [0.81, 2.30]

3.1 Participants with diminutive neoplastic lesions in the distal colon in studies with single intubation

1

259

Odds Ratio (M‐H, Fixed, 95% CI)

1.34 [0.56, 3.22]

3.2 Participants with diminutive neoplastic lesions in the distal colon in studies with double intubation

1

292

Odds Ratio (M‐H, Fixed, 95% CI)

1.38 [0.72, 2.64]

Figuras y tablas -
Comparison 6. Number of participants with at least one diminutive neoplastic lesion detected with each intervention
Comparison 7. Number of participants with three or more neoplastic lesions detected with each intervention

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of participants with 3 or more adenomas Show forest plot

5

1669

Odds Ratio (M‐H, Fixed, 95% CI)

1.34 [0.96, 1.87]

1.1 Number of participants with 3 or more adenomas in studies with single intubation

2

519

Odds Ratio (M‐H, Fixed, 95% CI)

4.63 [1.99, 10.80]

1.2 Number of participants with 3 or more adenomas in studies with double intubation

1

292

Odds Ratio (M‐H, Fixed, 95% CI)

1.78 [0.68, 4.65]

1.3 Studies that used high definition colonoscopy in the control group

2

858

Odds Ratio (M‐H, Fixed, 95% CI)

0.86 [0.57, 1.31]

Figuras y tablas -
Comparison 7. Number of participants with three or more neoplastic lesions detected with each intervention